Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR with or without lenalidomide maintenance for newly treated indolent B-cell lymphoma and elderly mantle cell lymphoma
ChiCTR2200056288Phase 4Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenalidomide, bendamustine and rituximab in mature B-cell lymphoma and mantle cell lymphoma (MCL) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: overall response rate. Started Apr 2021; status: completed.
02
Drugs
lenalidomidebendamustinerituximab
03
Conditions
mature B-cell lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2200056288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056288.